奥拉西坦的临床前药理学研究

摘要/Abstract

摘要： 促智药奥拉西坦的问世已有二十余年,国内外对其药理学特征进行了广泛而深入的研究。作为一个在一般药理学上无活性、无毒的认知增强剂,它具备良好的药代动力学特性,其药理作用包括对学习记忆的改善作用以及一定的神经保护作用,其作用机制可能涉及:对中枢胆碱能系统的作用以及其它与认知相关的递质系统(如谷氨酸系统、单胺递质系统)与胆碱能系统的相互作用;对长时程增强的诱导和维持作用;对蛋白激酶C的激活作用;对脑代谢的改善作用;以及外周类固醇激素的影响等。

关键词: 奥拉西坦, 促智药, 认知增强剂, 学习记忆, 神经保护

Abstract: It has been more than 20 years since the birth of nootropic drug oxiracetam, extensive and deep research has been focused on its pharmacological features in china and abroad. As a general pharmacologically inactive and non-toxic cognition enhancer, it possesses good pharmacokinetics characteristics. The pharmacological effects of oxiracetam include the improvement of learning and memory and neuroprotective function. The mechanism of its action may involve: the effect on central acetylcholine system and the interaction between other neurotransmitter systems associated with cognition (such as glutamate system, monoamine neurotransmitter system) and the cholinergic system, induction and maintenance of LTP, activation of protein kinase C, promotion of brain metabolism, the impact of peripheral steroid hormones, etc.

Key words: Oxiracetam, Nootropic, Cognition enhancer, Learning and Memory, Neuroprotective

中图分类号:

R961

金磊, 李博, 叶雷, 蔡云红, 荣祖元. 奥拉西坦的临床前药理学研究[J]. 中国临床药理学与治疗学, 2011, 16(3): 354-360.

JIN Lei, LI Bo, YE Lei, CAI Yun-Hong, RONG Zu-Yuan. Preclinical pharmacology research of oxiracetam[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 354-360.

参考文献

[1] Giurgea C. Pharmacology of integrative activity of the brain.Attempt at nootropic concept in psychopharmacology[J]. Actual Pharmacol (Paris),1972, 25:115-156.
[2] Skondia V. Criteria for clinical development and classification of nootropic drugs[J].Clin Ther,1979, 2:316-332.
[3] Bostrom N, Sandberg A. Cognitive enhancement:methods, ethics, regulatory challenges[J]. Sci Eng Ethics, 2009, 15:311-341.
[4] Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. The way forward[J].Drugs,1997, 53(5):752-768.
[5] Ammassari-Teule M, D'Amato FR, Sansone M, et al. Enhancement of radial maze performances in CD1 mice after prenatal exposure to oxiracetam:possible role of sustained investigative responses developed during ontogeny[J].Physiol Behav,1988, 42(3):281-285.
[6] Ammassari-Teule M, D'Amato FR, Sansone M, et al. Avoidance facilitation in adult mice by prenatal administration of the nootropic drug oxiracetam[J].Pharmacol Res Commun,1986, 18(12):1169-1176.
[7] Giovannini MG, Spignoli G, Magnani M, et al. Interaction between cognition enhancing agents and brain acetylcholine[J].Pharmacol Res Commun,1988, 20(suppl 2):181.
[8] Spignoli G, Pedata F, Giovannelli L, et al. Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition[J].Clin Neuropharmacol,1986, 9(Suppl 3) :39-47.
[9] Bartolini L, Casamenti F, Pepeu G. Aniracetam restores object recognition impaired by age, scopolamine,and nucleus basalis lesions[J].Pharmacol Biochem Behave,1996, 53(2):277-283.
[10] Raiteri M, Costa R, Marchi M. Effects of oxiracetam on neurotransmitter release from rat hippocampus slices and synaptosomes[J].Neurosci Lett,1992, 145(1):109-113.
[11] Forloni G, Angeretti N, Amoroso D, et al. Decrease in [3H] hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam[J].Brain Res,1990, 530(1):156-160.
[12] Hall ED, Von Voigtlander PF. Facilitatoty effects of piracetam on excitability of motor nerve terminals and neuromuscular transmission[J].Neuropharmacology,1987, 26:1573- 1579.
[13] Consolo S, Salmoiraghi P, Amoroso D, et al. Treatment with oxiracetam or choline restores cholinergic biochemical and pharmacological activities in striata of decorticated rats[J].J Neurochem,1990, 54(2):571-577.
[14] Ammassari-Teule M, Castellano C, Sansone M. Enhancement by oxiracetam of passive avoidance improvement induced by the presynaptic muscarinic antagonist secoverine in mice[J].Behav Brain Res,1992, 47:93-95.
[15] Sansone M, Castellano C, Battaglia M, et al. Effects of oxiracetam-nicotine combinations on active and passive avoidance learning in mice[J].Pharmacol Biochem Behav,1991, 39:197-200.
[16] Mochizuki D, Sugiyama S, Shinoda Y. Biochemical studies of oxiracetam (CT-848) on cholinergic neurons [J].Nippon Yakurigaku Zasshi, 1992, 99(1):27-35.
[17] Sansone M, Castellano C, Palazzesi S, et al. Effects of oxiracetam,physostigmine,and their combination on active and passive avoidance learning in mice[J].Pharmacol Biochem Behav,1993, 44(2):451-455.
[18] Hlinák Z, Krejcí I. Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice[J].Behav Brain Res,2000, 117(1/2):147-151.
[19] Paoli F, Spignoli G, Pepeu G. Oxiracetam and D-pyro-glutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate[J].Psychopharmacology,1990, 100:130-131.
[20] Belfiore P, Ponzio F, Biagetti R, et al. Oxiracetam prevents the hippocampal cholinergic hypofunction induced by receptor NMDA blocker AP7[J].Neurosci Lett,1992, 143:127-130.
[21] Marchi M, Besana E, Raiteri M. Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices[J]. Eur J Pharmacol,1990, 185:247-249.
[22] Lu Y, Wehner JM. Enhancement of contextual fear-conditioning by putative (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice[J].Brain Res,1997, 768(1/2):197-207.
[23] Nicoletti F, Casabona G, Genazzani AA, et al. Excitatory amino acids and neuronal plasticity:modulation of AMPA receptors as a novel substrate for the action of nootropic drugs[J].Funct Neurol,1992, 7(5):413-422.
[24] Pugliese AM, Corradetti R, Ballerini L, et al.Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices[J] Br J Pharmacol,1990, 99(1):189-193.
[25] Abe E, Murai S, Saito H, et al. Effects of nefiracetam,a novel pyrrolidone derivative,on brain monoamine metabolisms in mice[J].J Neural Transm Gen Sect,1992, 90(2):125-136.
[26] Giovannini MG, Spignoli G, Carla V, et al. A decrease in brain catecholamines prevents oxiracetam antagonism of the effects of scopolamine on memory and brain acetylcholine[J].Pharmacol Res,1991, 24:395-405.
[27] Mondadori C, Ducret T, Petschke F. Blockade of the nootropic action of piracetam-like nootropics by adrenalectomy: an effect of dosage[J] ? Behav Brain Res,1989, 34(1/2):155-158.
[28] Mondadori C, Bhatnagar A, Borkowski J, et al. Involvement of a steroidal component in the mechanism of action of piracetam-like nootropics [J].Brain Res,1990, 506(1):101-108.
[29] Mondadori C, Ducret T, Häusler A. Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics[J].Psychopharmacology (Berl),1992, 108(1/2):11-15.
[30] Dudkin SM, Polev PV, Soldatov NM. Calcium entry blockers and oxiracetam have opposite effects on the density of dihydropyridine receptors in rat cerebral cortex[J]. Bruin Rex,1990, 525: 319-321.
[31] Govoni S, Lucchi L, Battaini F, et al. Protein kinase C increase in rat brain cortical membranes may be promoted by cognition enhancing drugs[J].Life Sci,1992, 50(16):125-128.
[32] Fordyce DE, Clark VJ, Paylor R, et al. Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning-impaired DBA/2 mice[J].Brain Res,1995, 672(1/2):170-176.
[33] Nicolaus BJR. Chemistry and Pharmacology of Nootropics[J].Drug Dev Res,1982, 2:463-474.
[34] Nardella C, Terracina L, Brunetti M, et al. Choline incorporation into phospholipids in brain areas from spontaneously hypertensive rats:effect of oxiracetam treatment[J].Farmaco,1991, 46(9):1051-1059.
[35] Gabryel B, Trzeciak HI, Pudedko A, et al. Influence of piracetam and oxiracetam on the content of high-energy phosphates and morphometry of astrocytes in vitro[J].Pol J Pharmacol,1999, 51(6):485-495.
[36] Hokonohara T, Sako K, Shinoda Y, et al. The effects of oxiracetam (CT-848) on local cerebral glucose utilization after focal cerebral ischemia in rats[J].Jpn J Pharmacol,1992, 58(2):127-135.
[37] Gschwind HP, Schiitz H, Wigger N, et al.Absorption and disposition of 14C-labelled oxiracetam in rat,dog and man[J].Eur J Drug Metab Pharmacokinet,1992, 17:67-82.
[38] Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease[J].Clin Pharmacokinet,1995, 29(2):110-129.
[39] Ponzio F, Pozzi O, Banfi S, et al. Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam.Oxiracetam:brain entry and pharmacological effects[J]. Pharmacopsychiatry,1989, 22(Suppl 2):111-115.